 Martin McCarter
Concepts (810)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 52 | 2025 | 759 | 7.750 |
Why?
| | Esophageal Neoplasms | 29 | 2025 | 348 | 5.090 |
Why?
| | Skin Neoplasms | 34 | 2024 | 849 | 4.530 |
Why?
| | Adenocarcinoma | 29 | 2025 | 925 | 3.290 |
Why?
| | Esophagectomy | 20 | 2024 | 135 | 3.280 |
Why?
| | Myeloid-Derived Suppressor Cells | 6 | 2025 | 76 | 2.570 |
Why?
| | Sentinel Lymph Node Biopsy | 23 | 2022 | 117 | 2.540 |
Why?
| | Gastrointestinal Stromal Tumors | 10 | 2022 | 41 | 2.080 |
Why?
| | Neoadjuvant Therapy | 15 | 2025 | 465 | 1.630 |
Why?
| | Sentinel Lymph Node | 9 | 2022 | 49 | 1.600 |
Why?
| | Rectal Neoplasms | 8 | 2024 | 159 | 1.580 |
Why?
| | Dendritic Cells | 13 | 2019 | 499 | 1.540 |
Why?
| | T-Lymphocytes, Regulatory | 11 | 2022 | 409 | 1.520 |
Why?
| | Pancreatic Neoplasms | 15 | 2024 | 928 | 1.510 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2024 | 1149 | 1.450 |
Why?
| | Stomach Neoplasms | 6 | 2025 | 128 | 1.370 |
Why?
| | Lymphatic Metastasis | 20 | 2023 | 331 | 1.290 |
Why?
| | Neoplasm Staging | 33 | 2025 | 1471 | 1.260 |
Why?
| | Tumor Escape | 4 | 2017 | 49 | 1.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1963 | 1.120 |
Why?
| | Hyperthermia, Induced | 4 | 2020 | 120 | 1.080 |
Why?
| | Humans | 218 | 2026 | 145474 | 1.070 |
Why?
| | Sarcoma | 8 | 2026 | 207 | 1.070 |
Why?
| | Colonic Neoplasms | 7 | 2024 | 257 | 1.060 |
Why?
| | HIV-1 | 17 | 2025 | 908 | 1.050 |
Why?
| | Lymph Nodes | 15 | 2023 | 503 | 1.030 |
Why?
| | Middle Aged | 107 | 2026 | 36215 | 1.030 |
Why?
| | Neoplasms | 14 | 2025 | 2906 | 1.010 |
Why?
| | Anus Neoplasms | 3 | 2024 | 32 | 1.010 |
Why?
| | Aged | 89 | 2026 | 26153 | 0.990 |
Why?
| | Peritoneal Neoplasms | 4 | 2024 | 104 | 0.960 |
Why?
| | Hyperglycemia | 3 | 2020 | 379 | 0.940 |
Why?
| | Postoperative Complications | 21 | 2025 | 2970 | 0.940 |
Why?
| | Retrospective Studies | 57 | 2026 | 17291 | 0.940 |
Why?
| | Intestinal Neoplasms | 2 | 2024 | 30 | 0.930 |
Why?
| | Cytoreduction Surgical Procedures | 5 | 2024 | 69 | 0.920 |
Why?
| | HIV Infections | 21 | 2025 | 3193 | 0.890 |
Why?
| | CD4-Positive T-Lymphocytes | 14 | 2025 | 1140 | 0.890 |
Why?
| | Prognosis | 30 | 2025 | 4316 | 0.890 |
Why?
| | Laparoscopy | 8 | 2024 | 481 | 0.870 |
Why?
| | Colorectal Neoplasms | 8 | 2025 | 866 | 0.860 |
Why?
| | Intestine, Small | 2 | 2024 | 167 | 0.840 |
Why?
| | Survival Rate | 23 | 2025 | 2090 | 0.830 |
Why?
| | Male | 121 | 2026 | 72842 | 0.820 |
Why?
| | Female | 132 | 2026 | 78844 | 0.810 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2024 | 38 | 0.800 |
Why?
| | Intestinal Mucosa | 10 | 2021 | 675 | 0.770 |
Why?
| | Pancreaticoduodenectomy | 7 | 2021 | 137 | 0.740 |
Why?
| | Lymph Node Excision | 8 | 2022 | 173 | 0.730 |
Why?
| | Tretinoin | 3 | 2023 | 125 | 0.720 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 102 | 0.700 |
Why?
| | Lymphocyte Activation | 11 | 2018 | 1132 | 0.690 |
Why?
| | T-Lymphocytes | 8 | 2024 | 1996 | 0.690 |
Why?
| | Pelvic Exenteration | 4 | 2019 | 12 | 0.660 |
Why?
| | Gastrointestinal Microbiome | 9 | 2025 | 767 | 0.660 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2022 | 72 | 0.650 |
Why?
| | Anastomotic Leak | 4 | 2024 | 45 | 0.630 |
Why?
| | Radiosurgery | 4 | 2020 | 399 | 0.620 |
Why?
| | Adult | 69 | 2026 | 40777 | 0.620 |
Why?
| | Survival Analysis | 16 | 2022 | 1374 | 0.620 |
Why?
| | Splenectomy | 1 | 2020 | 61 | 0.610 |
Why?
| | Chemoradiotherapy | 6 | 2024 | 239 | 0.610 |
Why?
| | Pancreatic Cyst | 2 | 2017 | 50 | 0.590 |
Why?
| | Ipilimumab | 2 | 2019 | 40 | 0.580 |
Why?
| | Piperazines | 5 | 2014 | 375 | 0.580 |
Why?
| | Myeloid Cells | 3 | 2020 | 147 | 0.580 |
Why?
| | Ischemic Preconditioning | 3 | 2024 | 47 | 0.570 |
Why?
| | Spleen | 6 | 2017 | 508 | 0.570 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 142 | 0.560 |
Why?
| | Granulocytes | 2 | 2017 | 81 | 0.560 |
Why?
| | Pyrimidines | 5 | 2014 | 530 | 0.540 |
Why?
| | Leukocytes, Mononuclear | 5 | 2021 | 574 | 0.540 |
Why?
| | Induction Chemotherapy | 3 | 2024 | 88 | 0.530 |
Why?
| | Monocytes | 2 | 2020 | 539 | 0.530 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 28 | 0.530 |
Why?
| | Antineoplastic Agents | 9 | 2024 | 2214 | 0.520 |
Why?
| | Combined Modality Therapy | 15 | 2024 | 1266 | 0.510 |
Why?
| | Aged, 80 and over | 28 | 2024 | 8333 | 0.510 |
Why?
| | Pylorus | 1 | 2017 | 17 | 0.500 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 12 | 0.500 |
Why?
| | Mucous Membrane | 5 | 2024 | 128 | 0.490 |
Why?
| | Time-to-Treatment | 4 | 2025 | 251 | 0.490 |
Why?
| | Follow-Up Studies | 20 | 2025 | 5423 | 0.490 |
Why?
| | CD8-Positive T-Lymphocytes | 6 | 2024 | 919 | 0.490 |
Why?
| | Soft Tissue Neoplasms | 3 | 2022 | 131 | 0.470 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 46 | 0.470 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 198 | 0.470 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 59 | 0.470 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 561 | 0.460 |
Why?
| | Treatment Outcome | 29 | 2026 | 11772 | 0.460 |
Why?
| | Leucovorin | 2 | 2019 | 98 | 0.460 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2024 | 153 | 0.450 |
Why?
| | Liver Neoplasms | 6 | 2024 | 776 | 0.440 |
Why?
| | Vitamin B Complex | 1 | 2014 | 39 | 0.420 |
Why?
| | Immune Tolerance | 4 | 2016 | 385 | 0.410 |
Why?
| | Lymphocytes | 3 | 2021 | 376 | 0.410 |
Why?
| | Esophagogastric Junction | 4 | 2024 | 55 | 0.410 |
Why?
| | Salvage Therapy | 2 | 2014 | 165 | 0.410 |
Why?
| | Minimally Invasive Surgical Procedures | 6 | 2023 | 189 | 0.400 |
Why?
| | Pancreatectomy | 5 | 2024 | 289 | 0.400 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 109 | 0.390 |
Why?
| | Pelvis | 1 | 2014 | 125 | 0.390 |
Why?
| | Ear, External | 1 | 2013 | 21 | 0.390 |
Why?
| | Mohs Surgery | 1 | 2013 | 29 | 0.390 |
Why?
| | Mutation | 9 | 2025 | 4075 | 0.380 |
Why?
| | Up-Regulation | 5 | 2025 | 847 | 0.380 |
Why?
| | Immunity, Innate | 5 | 2025 | 835 | 0.370 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 2017 | 132 | 0.370 |
Why?
| | Microbiota | 5 | 2024 | 730 | 0.370 |
Why?
| | B-Lymphocytes | 4 | 2025 | 870 | 0.370 |
Why?
| | Biopsy | 3 | 2023 | 1082 | 0.370 |
Why?
| | Abdominal Neoplasms | 3 | 2025 | 47 | 0.370 |
Why?
| | Prospective Studies | 22 | 2025 | 8057 | 0.370 |
Why?
| | Retroperitoneal Neoplasms | 4 | 2026 | 28 | 0.360 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 734 | 0.360 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2014 | 641 | 0.360 |
Why?
| | Hematologic Diseases | 1 | 2012 | 66 | 0.360 |
Why?
| | Anastomosis, Surgical | 3 | 2024 | 162 | 0.350 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.350 |
Why?
| | Biomarkers, Tumor | 6 | 2025 | 1321 | 0.350 |
Why?
| | Receptors, CCR5 | 3 | 2021 | 60 | 0.350 |
Why?
| | Cytokines | 8 | 2021 | 2067 | 0.340 |
Why?
| | Cell Movement | 6 | 2025 | 959 | 0.340 |
Why?
| | Dasatinib | 2 | 2024 | 58 | 0.330 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 329 | 0.330 |
Why?
| | Palliative Care | 1 | 2019 | 1020 | 0.320 |
Why?
| | Granzymes | 2 | 2021 | 49 | 0.320 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 22 | 0.320 |
Why?
| | Killer Cells, Natural | 3 | 2025 | 480 | 0.310 |
Why?
| | Thrombelastography | 2 | 2024 | 192 | 0.310 |
Why?
| | Esophageal Achalasia | 2 | 2021 | 29 | 0.310 |
Why?
| | Benzamides | 5 | 2014 | 226 | 0.300 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 138 | 0.300 |
Why?
| | Homosexuality, Male | 3 | 2021 | 231 | 0.300 |
Why?
| | Databases, Factual | 7 | 2025 | 1490 | 0.300 |
Why?
| | Young Adult | 20 | 2025 | 14218 | 0.300 |
Why?
| | Interferon-gamma | 6 | 2019 | 784 | 0.300 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 14 | 0.290 |
Why?
| | Immunotherapy | 5 | 2024 | 666 | 0.280 |
Why?
| | Butyrates | 2 | 2021 | 66 | 0.280 |
Why?
| | Interleukin-15 | 2 | 2021 | 95 | 0.280 |
Why?
| | Membrane Glycoproteins | 3 | 2015 | 499 | 0.280 |
Why?
| | Medical Oncology | 4 | 2022 | 339 | 0.280 |
Why?
| | Barrett Esophagus | 3 | 2020 | 169 | 0.280 |
Why?
| | Immunity, Mucosal | 3 | 2016 | 98 | 0.280 |
Why?
| | Neoplasm Metastasis | 4 | 2025 | 688 | 0.270 |
Why?
| | Cell Differentiation | 5 | 2016 | 2046 | 0.270 |
Why?
| | Chemotherapy, Adjuvant | 9 | 2023 | 423 | 0.270 |
Why?
| | Wounds and Injuries | 4 | 2009 | 961 | 0.270 |
Why?
| | Interleukin-10 | 4 | 2025 | 309 | 0.270 |
Why?
| | Antigens, Neoplasm | 3 | 2024 | 271 | 0.270 |
Why?
| | Inflammation Mediators | 2 | 2018 | 506 | 0.270 |
Why?
| | Blood Preservation | 2 | 2009 | 346 | 0.260 |
Why?
| | Disease-Free Survival | 8 | 2019 | 767 | 0.260 |
Why?
| | Prostatic Neoplasms | 1 | 2014 | 978 | 0.250 |
Why?
| | Nomograms | 2 | 2019 | 59 | 0.250 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 13 | 0.250 |
Why?
| | General Surgery | 2 | 2007 | 206 | 0.250 |
Why?
| | Immunocompromised Host | 1 | 2008 | 202 | 0.250 |
Why?
| | Dysbiosis | 3 | 2021 | 187 | 0.250 |
Why?
| | Colon | 3 | 2021 | 309 | 0.250 |
Why?
| | Cells, Cultured | 9 | 2021 | 4148 | 0.240 |
Why?
| | Mice | 25 | 2025 | 18329 | 0.240 |
Why?
| | Th2 Cells | 2 | 2005 | 175 | 0.240 |
Why?
| | Splenic Neoplasms | 1 | 2006 | 5 | 0.240 |
Why?
| | Lymphangioma | 1 | 2006 | 9 | 0.240 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 225 | 0.240 |
Why?
| | Time Factors | 12 | 2024 | 7123 | 0.240 |
Why?
| | Forkhead Transcription Factors | 1 | 2007 | 207 | 0.240 |
Why?
| | Pelvic Neoplasms | 3 | 2012 | 24 | 0.240 |
Why?
| | Population Surveillance | 2 | 2021 | 484 | 0.230 |
Why?
| | Transplantation Immunology | 1 | 2005 | 29 | 0.230 |
Why?
| | Ecotype | 1 | 2025 | 15 | 0.230 |
Why?
| | Receptors, Cell Surface | 2 | 2021 | 372 | 0.230 |
Why?
| | Macrophages, Peritoneal | 3 | 2005 | 89 | 0.230 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2025 | 48 | 0.230 |
Why?
| | Mice, Inbred BALB C | 6 | 2024 | 1261 | 0.230 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2025 | 41 | 0.230 |
Why?
| | Exome | 2 | 2017 | 227 | 0.230 |
Why?
| | Vena Cava, Inferior | 1 | 2026 | 83 | 0.230 |
Why?
| | Signal Transduction | 10 | 2025 | 5216 | 0.220 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 1 | 2005 | 14 | 0.220 |
Why?
| | Mentors | 1 | 2007 | 217 | 0.220 |
Why?
| | Circulating Tumor DNA | 1 | 2025 | 46 | 0.220 |
Why?
| | Neuroendocrine Tumors | 2 | 2017 | 119 | 0.220 |
Why?
| | Cellular Microenvironment | 1 | 2025 | 93 | 0.220 |
Why?
| | Catheter Ablation | 4 | 2016 | 355 | 0.220 |
Why?
| | Computational Biology | 3 | 2025 | 669 | 0.220 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 14 | 0.220 |
Why?
| | Culture Media, Conditioned | 4 | 2011 | 112 | 0.210 |
Why?
| | Radiation Injuries | 2 | 2021 | 149 | 0.210 |
Why?
| | Tumor Hypoxia | 1 | 2024 | 7 | 0.210 |
Why?
| | Nevus, Pigmented | 1 | 2005 | 35 | 0.210 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 293 | 0.210 |
Why?
| | Virus Replication | 5 | 2017 | 521 | 0.210 |
Why?
| | Metastasectomy | 1 | 2024 | 19 | 0.210 |
Why?
| | Th1 Cells | 2 | 2019 | 139 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2005 | 181 | 0.210 |
Why?
| | Gastrectomy | 3 | 2025 | 166 | 0.210 |
Why?
| | Hepatectomy | 3 | 2024 | 274 | 0.210 |
Why?
| | Lymphangiogenesis | 1 | 2004 | 27 | 0.200 |
Why?
| | Mice, Nude | 2 | 2024 | 679 | 0.200 |
Why?
| | Interferon-alpha | 3 | 2015 | 193 | 0.200 |
Why?
| | B7-H1 Antigen | 2 | 2024 | 244 | 0.200 |
Why?
| | Lymphocyte Count | 5 | 2017 | 164 | 0.200 |
Why?
| | Cohort Studies | 7 | 2025 | 6013 | 0.200 |
Why?
| | Carcinoma | 2 | 2006 | 225 | 0.200 |
Why?
| | Ruminococcus | 2 | 2021 | 8 | 0.200 |
Why?
| | In Vitro Techniques | 5 | 2019 | 1048 | 0.200 |
Why?
| | Pseudomonas Infections | 1 | 2025 | 230 | 0.200 |
Why?
| | Flow Cytometry | 6 | 2017 | 1162 | 0.200 |
Why?
| | Paget Disease, Extramammary | 1 | 2003 | 4 | 0.200 |
Why?
| | Immunophenotyping | 3 | 2025 | 319 | 0.200 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 44 | 0.200 |
Why?
| | Esophageal Stenosis | 1 | 2024 | 60 | 0.200 |
Why?
| | Feces | 4 | 2021 | 495 | 0.190 |
Why?
| | Cannabinoids | 1 | 2025 | 184 | 0.190 |
Why?
| | Erythrocytes | 1 | 2009 | 748 | 0.190 |
Why?
| | Adolescent | 15 | 2019 | 22529 | 0.190 |
Why?
| | Animals | 28 | 2025 | 38030 | 0.190 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 10 | 0.190 |
Why?
| | Bacteria | 3 | 2018 | 765 | 0.190 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 231 | 0.190 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 78 | 0.190 |
Why?
| | Specialties, Surgical | 1 | 2023 | 82 | 0.190 |
Why?
| | Intestines | 2 | 2017 | 354 | 0.190 |
Why?
| | Transforming Growth Factor beta | 4 | 2015 | 474 | 0.190 |
Why?
| | Protein-Energy Malnutrition | 2 | 2003 | 7 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 101 | 0.180 |
Why?
| | Lysophospholipids | 1 | 2023 | 80 | 0.180 |
Why?
| | Cell Count | 2 | 2017 | 319 | 0.180 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 188 | 0.180 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 562 | 0.180 |
Why?
| | Cryosurgery | 2 | 2019 | 46 | 0.180 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 17 | 0.180 |
Why?
| | Ampulla of Vater | 2 | 2024 | 40 | 0.180 |
Why?
| | HIV Seropositivity | 1 | 2022 | 119 | 0.180 |
Why?
| | Preoperative Care | 3 | 2018 | 380 | 0.180 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 38 | 0.180 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 39 | 0.180 |
Why?
| | Imatinib Mesylate | 5 | 2014 | 77 | 0.180 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3542 | 0.170 |
Why?
| | Patient Selection | 3 | 2014 | 738 | 0.170 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 168 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 6 | 2016 | 2769 | 0.170 |
Why?
| | Esophagoscopy | 2 | 2020 | 223 | 0.170 |
Why?
| | Acinetobacter | 1 | 2021 | 16 | 0.170 |
Why?
| | Germinal Center | 2 | 2025 | 64 | 0.170 |
Why?
| | Critical Pathways | 1 | 2022 | 109 | 0.170 |
Why?
| | Carcinoma in Situ | 1 | 2001 | 44 | 0.170 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 177 | 0.170 |
Why?
| | Seminoma | 1 | 2021 | 20 | 0.170 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
| | Disease Progression | 2 | 2022 | 2864 | 0.170 |
Why?
| | Glucose | 3 | 2020 | 1048 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2025 | 308 | 0.160 |
Why?
| | Gamma Rays | 1 | 2021 | 57 | 0.160 |
Why?
| | Interleukin-2 | 5 | 2022 | 440 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 679 | 0.160 |
Why?
| | Carcinoma, Lobular | 1 | 2001 | 56 | 0.160 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2001 | 89 | 0.160 |
Why?
| | Delivery of Health Care | 2 | 2021 | 946 | 0.160 |
Why?
| | Transcriptome | 2 | 2025 | 1038 | 0.160 |
Why?
| | Risk Factors | 12 | 2024 | 10885 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 78 | 0.160 |
Why?
| | Group II Phospholipases A2 | 1 | 2020 | 10 | 0.160 |
Why?
| | Diarrhea | 3 | 2008 | 193 | 0.160 |
Why?
| | Bacterial Translocation | 2 | 2019 | 52 | 0.160 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.160 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 40 | 0.160 |
Why?
| | Interleukins | 2 | 2019 | 248 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 981 | 0.150 |
Why?
| | Software | 1 | 2025 | 680 | 0.150 |
Why?
| | Platelet Count | 1 | 2020 | 94 | 0.150 |
Why?
| | Guidelines as Topic | 2 | 2018 | 266 | 0.150 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 76 | 0.150 |
Why?
| | Neutrophils | 1 | 2025 | 1124 | 0.150 |
Why?
| | Basophils | 1 | 2020 | 52 | 0.150 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 77 | 0.150 |
Why?
| | Apoptosis | 5 | 2021 | 2440 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 218 | 0.150 |
Why?
| | Cell Proliferation | 6 | 2021 | 2507 | 0.150 |
Why?
| | United States | 14 | 2025 | 16098 | 0.150 |
Why?
| | Dacarbazine | 4 | 2012 | 100 | 0.150 |
Why?
| | Scalp | 1 | 2019 | 38 | 0.150 |
Why?
| | Sclerosing Solutions | 1 | 2019 | 10 | 0.150 |
Why?
| | Argon Plasma Coagulation | 1 | 2019 | 6 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2020 | 316 | 0.150 |
Why?
| | Germ-Free Life | 1 | 2019 | 33 | 0.150 |
Why?
| | Sclerotherapy | 1 | 2019 | 19 | 0.150 |
Why?
| | Gastric Bypass | 1 | 2021 | 126 | 0.150 |
Why?
| | Palatine Tonsil | 4 | 2025 | 54 | 0.150 |
Why?
| | CD4 Antigens | 2 | 2011 | 137 | 0.140 |
Why?
| | Haploinsufficiency | 1 | 2019 | 54 | 0.140 |
Why?
| | Patient Care Planning | 2 | 2016 | 170 | 0.140 |
Why?
| | Self Expandable Metallic Stents | 1 | 2019 | 17 | 0.140 |
Why?
| | Surgeons | 1 | 2023 | 340 | 0.140 |
Why?
| | Stomach | 3 | 2024 | 111 | 0.140 |
Why?
| | Nutritional Support | 1 | 2019 | 39 | 0.140 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 53 | 0.140 |
Why?
| | HLA-DR Antigens | 2 | 2011 | 220 | 0.140 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 48 | 0.140 |
Why?
| | Mastocytosis | 1 | 2019 | 14 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 219 | 0.140 |
Why?
| | Photochemotherapy | 1 | 2019 | 39 | 0.140 |
Why?
| | Intestinal Perforation | 1 | 2019 | 46 | 0.140 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.140 |
Why?
| | Decision Making | 2 | 2019 | 977 | 0.140 |
Why?
| | Environmental Restoration and Remediation | 1 | 2018 | 8 | 0.140 |
Why?
| | Skin Pigmentation | 1 | 2019 | 48 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2025 | 1443 | 0.140 |
Why?
| | Dilatation | 1 | 2019 | 71 | 0.140 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 80 | 0.140 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 105 | 0.140 |
Why?
| | Th17 Cells | 1 | 2019 | 101 | 0.140 |
Why?
| | Intestinal Obstruction | 1 | 2019 | 55 | 0.140 |
Why?
| | Survivors | 2 | 2015 | 523 | 0.140 |
Why?
| | Breast Neoplasms | 2 | 2001 | 2382 | 0.140 |
Why?
| | Esophagus | 1 | 2020 | 262 | 0.140 |
Why?
| | Fibrosis | 1 | 2021 | 559 | 0.140 |
Why?
| | Tissue and Organ Procurement | 1 | 2022 | 343 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Brachytherapy | 1 | 2019 | 132 | 0.130 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.130 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 176 | 0.130 |
Why?
| | Hospitals | 2 | 2021 | 732 | 0.130 |
Why?
| | Down-Regulation | 1 | 2020 | 618 | 0.130 |
Why?
| | HIV | 1 | 2019 | 251 | 0.130 |
Why?
| | Carcinoid Tumor | 1 | 2017 | 21 | 0.130 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 38 | 0.130 |
Why?
| | Viral Tropism | 1 | 2017 | 36 | 0.130 |
Why?
| | Food, Formulated | 1 | 1997 | 16 | 0.130 |
Why?
| | Risk Assessment | 4 | 2024 | 3747 | 0.130 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 26 | 0.130 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 28 | 0.130 |
Why?
| | Deglutition Disorders | 1 | 2019 | 154 | 0.130 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 328 | 0.130 |
Why?
| | src-Family Kinases | 1 | 2017 | 92 | 0.130 |
Why?
| | Laser Therapy | 1 | 2019 | 144 | 0.130 |
Why?
| | Liver | 4 | 2016 | 1896 | 0.130 |
Why?
| | Fatty Acids, Omega-3 | 1 | 1998 | 143 | 0.120 |
Why?
| | Chemotaxis, Leukocyte | 2 | 2025 | 114 | 0.120 |
Why?
| | Gastric Emptying | 1 | 2017 | 36 | 0.120 |
Why?
| | Enteral Nutrition | 2 | 2010 | 217 | 0.120 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 66 | 0.120 |
Why?
| | Arginine | 1 | 1998 | 264 | 0.120 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 237 | 0.120 |
Why?
| | Disease Management | 1 | 2021 | 653 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 992 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2025 | 1149 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 212 | 0.120 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 9 | 0.120 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 820 | 0.120 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 50 | 0.120 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 223 | 0.120 |
Why?
| | Nutritional Status | 1 | 2019 | 353 | 0.120 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 48 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2017 | 207 | 0.120 |
Why?
| | Immunologic Memory | 2 | 2016 | 368 | 0.120 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 21 | 0.120 |
Why?
| | Polysaccharides, Bacterial | 1 | 2016 | 69 | 0.120 |
Why?
| | Bystander Effect | 1 | 2016 | 19 | 0.120 |
Why?
| | Digestive System Surgical Procedures | 1 | 1997 | 112 | 0.120 |
Why?
| | Lymphocyte Depletion | 3 | 2013 | 132 | 0.120 |
Why?
| | Predictive Value of Tests | 6 | 2024 | 2121 | 0.120 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 99 | 0.120 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 27 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2024 | 418 | 0.110 |
Why?
| | Mortality | 1 | 2018 | 378 | 0.110 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 104 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 848 | 0.110 |
Why?
| | Morbidity | 3 | 2023 | 322 | 0.110 |
Why?
| | Exons | 3 | 2019 | 363 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 239 | 0.110 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2015 | 56 | 0.110 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 11 | 0.110 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 12 | 0.110 |
Why?
| | Perioperative Care | 1 | 2018 | 231 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1217 | 0.110 |
Why?
| | Adenoma | 1 | 2017 | 218 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1747 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 530 | 0.110 |
Why?
| | Postoperative Care | 1 | 1997 | 286 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 337 | 0.110 |
Why?
| | Ileus | 1 | 2014 | 13 | 0.110 |
Why?
| | Receptors, Ghrelin | 1 | 2014 | 7 | 0.110 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 92 | 0.110 |
Why?
| | Biomarkers | 3 | 2024 | 4295 | 0.110 |
Why?
| | Vinblastine | 2 | 2012 | 75 | 0.110 |
Why?
| | Viral Load | 5 | 2018 | 526 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 934 | 0.100 |
Why?
| | Endosonography | 1 | 2016 | 160 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2021 | 1164 | 0.100 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 886 | 0.100 |
Why?
| | Ethanol | 1 | 2019 | 631 | 0.100 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 65 | 0.100 |
Why?
| | Quality of Life | 3 | 2019 | 3204 | 0.100 |
Why?
| | Dietary Supplements | 1 | 1998 | 583 | 0.100 |
Why?
| | Blood Cell Count | 1 | 2013 | 55 | 0.100 |
Why?
| | Fluorouracil | 2 | 2019 | 231 | 0.100 |
Why?
| | Colectomy | 3 | 2008 | 106 | 0.100 |
Why?
| | Tumor Burden | 4 | 2022 | 325 | 0.100 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 204 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2664 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2016 | 881 | 0.100 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 88 | 0.100 |
Why?
| | RNA, Viral | 3 | 2013 | 692 | 0.090 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 372 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 477 | 0.090 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2013 | 73 | 0.090 |
Why?
| | Oligopeptides | 1 | 2014 | 267 | 0.090 |
Why?
| | Pilot Projects | 1 | 2018 | 1891 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2015 | 1997 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2378 | 0.090 |
Why?
| | Side-Population Cells | 1 | 2012 | 8 | 0.090 |
Why?
| | HIV Antibodies | 1 | 2013 | 61 | 0.090 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 527 | 0.090 |
Why?
| | Ablation Techniques | 1 | 2012 | 36 | 0.090 |
Why?
| | Cisplatin | 2 | 2012 | 345 | 0.090 |
Why?
| | Mice, Knockout | 4 | 2024 | 3124 | 0.090 |
Why?
| | Biological Therapy | 1 | 2012 | 28 | 0.090 |
Why?
| | Registries | 1 | 2021 | 2406 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 99 | 0.090 |
Why?
| | Hospital Mortality | 2 | 2016 | 1038 | 0.090 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 141 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 195 | 0.090 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 507 | 0.090 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 43 | 0.090 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 125 | 0.090 |
Why?
| | Elective Surgical Procedures | 1 | 2013 | 202 | 0.090 |
Why?
| | Gene Expression Profiling | 3 | 2025 | 1767 | 0.080 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.080 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 23 | 0.080 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 193 | 0.080 |
Why?
| | Ligands | 2 | 2023 | 665 | 0.080 |
Why?
| | Macrophages | 2 | 2001 | 1507 | 0.080 |
Why?
| | Multivariate Analysis | 4 | 2016 | 1547 | 0.080 |
Why?
| | Cell Separation | 2 | 2010 | 305 | 0.080 |
Why?
| | Extremities | 2 | 2022 | 141 | 0.080 |
Why?
| | Endocytosis | 1 | 2011 | 168 | 0.080 |
Why?
| | DNA Copy Number Variations | 2 | 2025 | 184 | 0.080 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 8 | 0.080 |
Why?
| | Interleukin-23 | 1 | 2010 | 16 | 0.080 |
Why?
| | Patient Care Team | 1 | 2016 | 696 | 0.080 |
Why?
| | Heparin | 1 | 2012 | 247 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 337 | 0.080 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 43 | 0.080 |
Why?
| | Gastric Fistula | 1 | 2010 | 9 | 0.080 |
Why?
| | Cutaneous Fistula | 1 | 2010 | 14 | 0.080 |
Why?
| | Antibodies, Neutralizing | 1 | 2013 | 340 | 0.080 |
Why?
| | Antigens, CD | 2 | 2015 | 558 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 242 | 0.080 |
Why?
| | Antiviral Agents | 1 | 2015 | 769 | 0.080 |
Why?
| | Vascular Surgical Procedures | 1 | 2013 | 343 | 0.070 |
Why?
| | Viremia | 1 | 2010 | 160 | 0.070 |
Why?
| | Escherichia coli | 1 | 2014 | 835 | 0.070 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1508 | 0.070 |
Why?
| | Rosaniline Dyes | 3 | 2007 | 15 | 0.070 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 148 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5983 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2016 | 867 | 0.070 |
Why?
| | Genomics | 2 | 2025 | 825 | 0.070 |
Why?
| | Cell Transplantation | 1 | 2009 | 39 | 0.070 |
Why?
| | Odds Ratio | 3 | 2019 | 1082 | 0.070 |
Why?
| | Double-Blind Method | 4 | 2014 | 2062 | 0.070 |
Why?
| | Immunoglobulins | 2 | 2023 | 162 | 0.070 |
Why?
| | Phenotype | 5 | 2019 | 3155 | 0.070 |
Why?
| | Paracrine Communication | 1 | 2009 | 67 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2024 | 673 | 0.070 |
Why?
| | Radiotherapy, Conformal | 1 | 2009 | 74 | 0.070 |
Why?
| | Hyalin | 1 | 2008 | 3 | 0.070 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2008 | 29 | 0.070 |
Why?
| | Dermatofibrosarcoma | 1 | 2008 | 7 | 0.070 |
Why?
| | Prosthesis Implantation | 1 | 2010 | 154 | 0.070 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 409 | 0.070 |
Why?
| | ROC Curve | 2 | 2024 | 617 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1189 | 0.070 |
Why?
| | Age Factors | 3 | 2019 | 3342 | 0.070 |
Why?
| | Gastrostomy | 1 | 2010 | 130 | 0.070 |
Why?
| | Interleukin-4 | 2 | 2007 | 207 | 0.070 |
Why?
| | ras Proteins | 1 | 2009 | 150 | 0.070 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 407 | 0.070 |
Why?
| | Chemokine CXCL12 | 1 | 2008 | 86 | 0.070 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2008 | 81 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 969 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 265 | 0.070 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 17 | 0.060 |
Why?
| | Logistic Models | 4 | 2016 | 2134 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2024 | 3623 | 0.060 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 82 | 0.060 |
Why?
| | Interleukin-1beta | 2 | 2019 | 389 | 0.060 |
Why?
| | Career Mobility | 1 | 2007 | 68 | 0.060 |
Why?
| | Deoxycytidine | 1 | 2008 | 220 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 599 | 0.060 |
Why?
| | Interleukin-6 | 4 | 1999 | 776 | 0.060 |
Why?
| | Phylogeny | 2 | 2024 | 917 | 0.060 |
Why?
| | alpha-Defensins | 1 | 2006 | 11 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2019 | 320 | 0.060 |
Why?
| | Length of Stay | 3 | 2019 | 1349 | 0.060 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1716 | 0.060 |
Why?
| | New York | 2 | 2023 | 128 | 0.060 |
Why?
| | Laparotomy | 1 | 2007 | 113 | 0.060 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 20 | 0.060 |
Why?
| | History, 20th Century | 1 | 2007 | 328 | 0.060 |
Why?
| | Watchful Waiting | 2 | 2018 | 90 | 0.060 |
Why?
| | Anticoagulants | 1 | 2012 | 748 | 0.060 |
Why?
| | Liquid Biopsy | 1 | 2025 | 15 | 0.060 |
Why?
| | Vascular Patency | 1 | 2026 | 121 | 0.060 |
Why?
| | Blood Transfusion | 1 | 2009 | 409 | 0.060 |
Why?
| | Pandemics | 2 | 2025 | 1707 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 49 | 0.060 |
Why?
| | Interleukin-17 | 2 | 2019 | 120 | 0.060 |
Why?
| | Collagen | 1 | 2008 | 457 | 0.060 |
Why?
| | Critical Care | 1 | 2012 | 702 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2009 | 624 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 858 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2024 | 441 | 0.060 |
Why?
| | Cell Division | 2 | 2005 | 756 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 274 | 0.060 |
Why?
| | Quality Control | 1 | 2025 | 161 | 0.060 |
Why?
| | Culture Media | 1 | 2005 | 161 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 39 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 61 | 0.050 |
Why?
| | Mice, Inbred Strains | 1 | 2005 | 396 | 0.050 |
Why?
| | Chromones | 1 | 2024 | 43 | 0.050 |
Why?
| | Nitric Oxide | 2 | 2001 | 892 | 0.050 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 30 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2008 | 293 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2007 | 303 | 0.050 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 39 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2005 | 2803 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 130 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 105 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 63 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 555 | 0.050 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 271 | 0.050 |
Why?
| | Quality Improvement | 1 | 2012 | 1295 | 0.050 |
Why?
| | Carcinoma, Renal Cell | 1 | 2026 | 230 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 354 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 25 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2005 | 276 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 506 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 40 | 0.050 |
Why?
| | Leadership | 1 | 2007 | 401 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2024 | 249 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 16 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 172 | 0.050 |
Why?
| | Antigens, CD1 | 2 | 2015 | 60 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2023 | 44 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 187 | 0.050 |
Why?
| | Pseudomonas aeruginosa | 1 | 2025 | 395 | 0.050 |
Why?
| | Axilla | 2 | 2017 | 51 | 0.050 |
Why?
| | Body Weight | 4 | 2003 | 971 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 118 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 312 | 0.040 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 16 | 0.040 |
Why?
| | Corticosterone | 1 | 2003 | 241 | 0.040 |
Why?
| | Technetium | 1 | 2001 | 10 | 0.040 |
Why?
| | Injections, Intradermal | 1 | 2001 | 11 | 0.040 |
Why?
| | Child | 4 | 2019 | 22707 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2007 | 479 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 78 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2003 | 135 | 0.040 |
Why?
| | NF-kappa B | 1 | 2005 | 666 | 0.040 |
Why?
| | Kidney Neoplasms | 1 | 2026 | 413 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 261 | 0.040 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 2001 | 6 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 334 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2001 | 115 | 0.040 |
Why?
| | Propionates | 1 | 2021 | 39 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 39 | 0.040 |
Why?
| | Leptin | 1 | 2003 | 248 | 0.040 |
Why?
| | Mediastinoscopy | 1 | 2021 | 5 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 439 | 0.040 |
Why?
| | Acetates | 1 | 2021 | 78 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2001 | 185 | 0.040 |
Why?
| | Neoplasm Transplantation | 3 | 2012 | 246 | 0.040 |
Why?
| | Glycoproteins | 2 | 2015 | 354 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 45 | 0.040 |
Why?
| | Cholangiography | 1 | 2000 | 10 | 0.040 |
Why?
| | Workload | 1 | 2002 | 168 | 0.040 |
Why?
| | Probability | 1 | 2001 | 307 | 0.040 |
Why?
| | Precision Medicine | 2 | 2016 | 459 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 259 | 0.040 |
Why?
| | Positron-Emission Tomography | 3 | 2008 | 343 | 0.040 |
Why?
| | Veterans | 1 | 2013 | 1635 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2025 | 1323 | 0.040 |
Why?
| | Thoracoscopy | 1 | 2020 | 60 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 674 | 0.040 |
Why?
| | Tissue Banks | 1 | 2020 | 17 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2025 | 485 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2001 | 205 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 428 | 0.040 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 22 | 0.040 |
Why?
| | Regression Analysis | 2 | 2019 | 1001 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 123 | 0.040 |
Why?
| | Quality of Health Care | 3 | 2012 | 692 | 0.040 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2019 | 3 | 0.040 |
Why?
| | Coloring Agents | 2 | 2012 | 89 | 0.040 |
Why?
| | Body Mass Index | 1 | 2008 | 2445 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 41 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 1025 | 0.040 |
Why?
| | Eating | 2 | 2003 | 387 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 50 | 0.040 |
Why?
| | Paclitaxel | 2 | 2012 | 257 | 0.040 |
Why?
| | Radiography | 2 | 2016 | 852 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 1300 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 583 | 0.040 |
Why?
| | Tight Junctions | 1 | 2019 | 82 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 461 | 0.040 |
Why?
| | Montana | 1 | 2018 | 18 | 0.040 |
Why?
| | United States Environmental Protection Agency | 1 | 2018 | 28 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 149 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 342 | 0.030 |
Why?
| | Mitogens | 1 | 1998 | 55 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2019 | 234 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2022 | 709 | 0.030 |
Why?
| | Keratins | 2 | 2010 | 171 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 89 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2002 | 740 | 0.030 |
Why?
| | Cachexia | 1 | 1999 | 74 | 0.030 |
Why?
| | Pedigree | 1 | 2019 | 515 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 534 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2018 | 193 | 0.030 |
Why?
| | Jejunostomy | 1 | 1997 | 14 | 0.030 |
Why?
| | Perioperative Period | 1 | 2017 | 70 | 0.030 |
Why?
| | Dinoprostone | 1 | 1998 | 180 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 117 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1480 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 159 | 0.030 |
Why?
| | Occipital Bone | 1 | 2017 | 18 | 0.030 |
Why?
| | Liver Circulation | 1 | 2016 | 12 | 0.030 |
Why?
| | Parotid Gland | 1 | 2017 | 17 | 0.030 |
Why?
| | Candidiasis | 1 | 1997 | 64 | 0.030 |
Why?
| | Femoral Fractures | 1 | 1998 | 84 | 0.030 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2016 | 37 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 84 | 0.030 |
Why?
| | Operative Time | 1 | 2017 | 181 | 0.030 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 185 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 635 | 0.030 |
Why?
| | Infection Control | 1 | 1998 | 173 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2008 | 288 | 0.030 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 259 | 0.030 |
Why?
| | Neck | 1 | 2017 | 108 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 221 | 0.030 |
Why?
| | Superinfection | 1 | 2016 | 5 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 87 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 425 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2016 | 27 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 1998 | 335 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2008 | 222 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 977 | 0.030 |
Why?
| | Host Specificity | 1 | 2016 | 33 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 442 | 0.030 |
Why?
| | Histones | 1 | 2021 | 666 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 81 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 172 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2238 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 500 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 104 | 0.030 |
Why?
| | Prevotella | 1 | 2015 | 26 | 0.030 |
Why?
| | Virion | 1 | 2015 | 108 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2015 | 186 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 468 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 142 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 741 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1674 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 494 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 431 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 5904 | 0.030 |
Why?
| | CD40 Antigens | 1 | 2015 | 90 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 598 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2010 | 1111 | 0.030 |
Why?
| | Glucocorticoids | 1 | 1999 | 531 | 0.030 |
Why?
| | Mitotic Index | 1 | 2014 | 25 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 946 | 0.030 |
Why?
| | Nausea | 1 | 2014 | 112 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 777 | 0.030 |
Why?
| | Vomiting | 1 | 2014 | 131 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 769 | 0.020 |
Why?
| | Colitis | 1 | 2016 | 280 | 0.020 |
Why?
| | Phosphorylation | 1 | 1998 | 1707 | 0.020 |
Why?
| | Caspase 1 | 1 | 2014 | 145 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 280 | 0.020 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 10 | 0.020 |
Why?
| | Autoantigens | 1 | 2016 | 427 | 0.020 |
Why?
| | Cell Lineage | 1 | 2015 | 377 | 0.020 |
Why?
| | Inflammation | 2 | 2019 | 2878 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3904 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3413 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2013 | 55 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 29 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 28 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 363 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2013 | 86 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2013 | 178 | 0.020 |
Why?
| | International Agencies | 1 | 2012 | 30 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1581 | 0.020 |
Why?
| | AIDS Vaccines | 1 | 2013 | 53 | 0.020 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 64 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 200 | 0.020 |
Why?
| | Thoracotomy | 1 | 2012 | 85 | 0.020 |
Why?
| | Hemorrhage | 1 | 1998 | 822 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 86 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 387 | 0.020 |
Why?
| | Homeostasis | 1 | 2016 | 642 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 310 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 294 | 0.020 |
Why?
| | APACHE | 1 | 2012 | 68 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 22 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 369 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2012 | 72 | 0.020 |
Why?
| | Internship and Residency | 1 | 2002 | 1267 | 0.020 |
Why?
| | Calcium | 1 | 1998 | 1190 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 202 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 546 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 782 | 0.020 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2013 | 167 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 306 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1243 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 269 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1476 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 393 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 318 | 0.020 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 22 | 0.020 |
Why?
| | Risk | 1 | 2013 | 919 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 328 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 613 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1100 | 0.020 |
Why?
| | CA-19-9 Antigen | 1 | 2010 | 34 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1327 | 0.020 |
Why?
| | Universities | 1 | 2013 | 445 | 0.020 |
Why?
| | Gastroscopy | 1 | 2010 | 18 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 637 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 153 | 0.020 |
Why?
| | Factor Xa Inhibitors | 1 | 2012 | 194 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2923 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1808 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2009 | 60 | 0.020 |
Why?
| | Keratin-20 | 1 | 2008 | 1 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2008 | 6 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 12 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 54 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 2129 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2013 | 466 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 137 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 46 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 140 | 0.020 |
Why?
| | Device Removal | 1 | 2010 | 142 | 0.020 |
Why?
| | Chemokine CX3CL1 | 1 | 2008 | 25 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 177 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 892 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2883 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 56 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 45 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2008 | 89 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 943 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2008 | 76 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 254 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 106 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1598 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2105 | 0.020 |
Why?
| | Quinazolines | 1 | 2009 | 266 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2188 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 307 | 0.020 |
Why?
| | Acute Disease | 2 | 2003 | 1036 | 0.020 |
Why?
| | Swine | 1 | 2010 | 825 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 505 | 0.020 |
Why?
| | Body Composition | 2 | 2003 | 693 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 5 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 224 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 232 | 0.010 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 174 | 0.010 |
Why?
| | Whole Body Imaging | 1 | 2006 | 29 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1041 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2597 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4560 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2007 | 333 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 408 | 0.010 |
Why?
| | Radiotherapy | 1 | 2006 | 204 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2170 | 0.010 |
Why?
| | Infant | 1 | 2019 | 10077 | 0.010 |
Why?
| | Patient Discharge | 1 | 2011 | 992 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 119 | 0.010 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2003 | 58 | 0.010 |
Why?
| | Adrenalectomy | 1 | 2003 | 68 | 0.010 |
Why?
| | Appetite Regulation | 1 | 2003 | 31 | 0.010 |
Why?
| | Drug Implants | 1 | 2003 | 83 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4553 | 0.010 |
Why?
| | Work Schedule Tolerance | 1 | 2002 | 51 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 365 | 0.010 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2002 | 98 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 42 | 0.010 |
Why?
| | Dactinomycin | 1 | 2001 | 23 | 0.010 |
Why?
| | Peritoneum | 1 | 2001 | 43 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 254 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2001 | 247 | 0.010 |
Why?
| | Continuity of Patient Care | 1 | 2002 | 297 | 0.010 |
Why?
| | Mifepristone | 1 | 1999 | 53 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1999 | 33 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 182 | 0.010 |
Why?
| | Candida albicans | 1 | 1997 | 61 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2028 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 3116 | 0.010 |
Why?
| | RNA | 1 | 2001 | 910 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1996 | 599 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 1193 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 7202 | 0.010 |
Why?
| | Kidney | 1 | 1997 | 1497 | 0.000 |
Why?
|
|
McCarter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|